A single report claimed that selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a genetically engineered mouse (GEM) melanoma model; moreover, treatment with ipilimumab did not restore the numbers of TIL [287]. This evidence concerns the gene BRAF and melanoma.